Chimeric Murine Polyomavirus Virus-Like Particles Induce Plasmodium Antigen-Specific CD8+ T Cell and Antibody Responses

David J. Pattinson1,2*, Simon H. Apte1, Nani Wibowo3, Yap P. Chuan3, Tania Rivera-Hernandez3, Penny L. Groves1, Linda H. Lua4, Anton P. J. Middelberg3 and Denise L. Doolan1,2*

1 Infectious Diseases Programme, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia, 2 Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia, 3 Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD, Australia, 4 Protein Expression Facility, University of Queensland, Brisbane, QLD, Australia

An effective vaccine against the Plasmodium parasite is likely to require the induction of robust antibody and T cell responses. Chimeric virus-like particles are an effective vaccine platform for induction of antibody responses, but their capacity to induce robust cellular responses and cell-mediated protection against pathogen challenge has not been established. To evaluate this, we produced chimeric constructs using the murine polyomavirus structural protein with surface-exposed CD8+ or CD4+ T cell or B cell repeat epitopes derived from the Plasmodium yoelii circumsporozoite protein, and assessed immunogenicity and protective capacity in a murine model. Robust CD8+ T cell responses were induced by immunization with the chimeric CD8+ T cell epitope virus-like particles, however CD4+ T cell responses were very low. The B cell chimeric construct induced robust antibody responses but there was no apparent synergy when T cell and B cell constructs were administered as a pool. A heterologous prime/boost regimen using plasmid DNA priming followed by a VLP boost was more effective than homologous VLP immunization for cellular immunity and protection. These data show that chimeric murine polyomavirus virus-like particles are a good platform for induction of CD8+ T cell responses as well as antibody responses.

Keywords: malaria, vaccine, circumsporozoite protein, virus-like particle, murine polyomavirus, cellular immunity, T cell responses, Plasmodium yoelii

INTRODUCTION

Although annual malaria related mortality rates have decreased by approximately 25% since 2010, improvements in morbidity and mortality have stabilized in recent years (World Malaria Report, 2017) and rebounds have been reported in some countries (Alonso et al., 2011). This is despite an annual financial investment of approximately US$2.7 billion, which includes malarial preventative measures such as residual spraying, insecticide-treated mosquito nets and preventative therapies (World Malaria Report, 2017). An effective vaccine is considered by many to be an essential tool for malaria disease control and eradication (Alonso et al., 2011). The ideal vaccine would target the pre-erythrocytic stage to induce sterile infection-blocking immunity which either prevents sporozoite invasion of the hepatocyte and/or halts the development of the parasite at the liver-stage; this would stop the development
of clinical symptoms of malaria which manifest during the blood-stage, as well as the transmission of malaria which occurs during the sexual stage. A partially effective vaccine which reduced liver-stage parasite burden and thus lowered blood-stage parasitemia to potentially below a threshold associated with clinical disease would, however, also be a useful tool.

Recently, GlaxoSmithKline achieved a significant milestone with Mosquirix™ (also known as RTS,S) by receiving a positive scientific opinion from the European Medicines Agency as the first malaria vaccine for the immunization of children aged 6 weeks to 17 months. This sub-unit virus-like particle (VLP) based vaccine targets the Plasmodium falciparum circumsporozoite protein (PfCSP) by combining a protein which includes multiple PfCSP B cell repeats and T cell epitopes fused with recombinant hepatitis B surface antigen (RTS), and recombinant wild-type hepatitis B surface antigen (S) (Gordon et al., 1995). These recombinant proteins combine to form stable VLPs, which are co-administered with the AS01 adjuvant (Agnandji et al., 2012). Disappointingly, clinical studies have shown that although RTS,S provided some protection in the first year after vaccination, this efficacy was very low and waned quickly (Tinto et al., 2015; Olotu et al., 2016) with negative efficacy and a rebound in later years demonstrated in a long-term follow-up study where RTS,S immunized 5–17 month children were more likely to be infected 5 years following vaccination (Olotu et al., 2016). These data emphasize the urgent need to identify new vaccine targets and vaccine delivery platforms that enhance immunogenicity and provide durable protection.

The CSP remains the most advanced subunit vaccine candidate, as a target for neutralizing antibodies prior to liver infection (Charoenvit et al., 1991; Mishra et al., 2012) and for T cell responses whilst in the hepatocyte (Grillot et al., 1990; Weiss et al., 1990, 1992; Franke et al., 1997, 2000). The induction of T cell or antibody mediated protection against sporozoite challenge has been demonstrated in murine and non-human primate models as well as humans by various vaccine platforms based on the CSP (Sedegah et al., 1994; Walsh et al., 2006; Mettens et al., 2008; Tewari et al., 2010; Tammainga et al., 2011; Noe et al., 2014; Janitze et al., 2016; Collins et al., 2017; Yoshida et al., 2018). Thus, the CSP is widely considered the antigen of choice for evaluating novel vaccine delivery platforms targeting the pre-erythrocytic stage of the parasite life cycle.

Whilst antibody responses generated by chimeric VLP immunizations using various VLP platforms with antigens from various pathogens in clinical studies are well-documented (reviewed in Kushnir et al., 2012), little research has been done to evaluate their efficacy at generating cellular responses. Chimeric VLPs using hamster and simian virus 40 polymerovirus structural proteins have shown antigen-specific cytotoxic T lymphocyte (CTL) responses with viral epitopes (Mazeike et al., 2012; Kawano et al., 2014), and a murine polymerovirus VLP with large HER-2–683 oncogene insert mouse study showed rejection and inhibition of antigen expressing tumor cells in vivo (Tegerstedt et al., 2005). Furthermore, both HPV16 L1 VLPs and their subunit component capsomers are potent inducers of CTL responses capable of tumor regression without adjuvants (Ohschlager et al., 2003).

In this study, we produced chimeric VLPs using the murine polymerovirus (MuPyV) (Salunke et al., 1986) by genomic insertion of either Plasmodium yoelii CSP CD8+ (280–288) (Weiss et al., 1992) or CD4+ (59–79) (Grillot et al., 1990) T cell epitopes, or the B cell repeat epitope (QGPGAP2) into a surface-exposed region of the VP1 structural protein (Middleberg et al., 2011). We selected the MuPyV-VP1 platform which has been extensively developed by our group, and can be produced in bacterial expression systems which can be purified at gram per liter levels (Liew et al., 2010). The proteins form pentameric capsomeres (Salunke et al., 1986) which can be chemically induced in vitro to self-assemble into VLPs (Chuan et al., 2008a; Middleberg et al., 2011; Rivera-Hernandez et al., 2013). We comprehensively evaluated antibody and T cell responses as well as protection from Plasmodium yoelii 17XNL sporozoite challenge using chimeric PyCSP surface exposed on murine polymerovirus VLP constructs delivered separately or pooled.

Consistent with previous results with the murine polymerovirus VLPs (Angrarai et al., 2013; Rivera-Hernandez et al., 2013; Wibowo et al., 2014; Seth et al., 2016; Tekewe et al., 2017), the Plasmodium B cell VLP was a strong inducer of antigen-specific antibody responses. Additionally, we showed that the VLP platform was capable of inducing robust VLP-induced CD8+ T cell responses. However, the VLPs did not stimulate a good CD4+ T cell response, and there was no apparent help provided by the CD4 VLP to the VLP-induced CD8+ T cell responses nor to the induced antibody titers. The VLP-induced CD8+ T cell responses were however enhanced using a heterologous DNA prime-boost regimen.

**MATERIALS AND METHODS**

**Plasmid Construction**

The plasmid pGEX-4T-1 (GE Healthcare Biosciences, UK) containing the murine polymerovirus VP1 sequence (M34958) was provided by Professor Robert Garcea (University of Colorado, USA). The VP1 sequence was modified by inserting an A61 restriction enzyme site flanked with Glycine-Serine linker sequences at position 293 and designated pGEX-VP1-S4-G4S (Middleberg et al., 2011). This allows for antigens to be inserted into a surface-exposed region of the VP1 protein with the linker sequences added to reduce structural interference from the insert on VLP formation. Codon optimized sequences representing defined PyCSP CD8+ (280–288) (Weiss et al., 1992) and CD4+ (59–79) (Grillot et al., 1990) T cell epitopes and the B cell repeat epitope (QGPGAP2) (Charoenvit et al., 1991) were separately inserted into the A61 site in pGEX-VP1-S4-G4S using standard molecular biology techniques to generate chimeric CD8+ or CD4+ T cell or B cell VLP constructs. All constructs were confirmed by Sanger sequencing.

**Protein Expression, Purification, and VLP Assembly**

Wild-type pGEX-VP1-S4-G4S, or the chimeric CD8+, CD4+, or B cell constructs were individually transformed into chemically competent E. coli Rosetta DE3 pLysS bacteria (Novagen, CA,
The GST-tagged VP1 proteins were expressed and purified as previously described (Chuan et al., 2008a; Middelberg et al., 2011). Briefly, bacteria inoculated Terrific Broth was incubated at 37°C and 180 RPM until the OD_{600} reached approximately 0.5, after which the culture was cooled to 26°C and induced by adding 0.2 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated overnight at 26°C and 180 RPM. The cultures were centrifuged and pellets lysed by sonication then filtered. Lysate was passed through a GSTrap HP affinity column (GE Healthcare, UK) and the purified protein was cleaved from the GST tag using thrombin (GE Healthcare, UK) and polished using a Superdex 200 10/300 GL column (GE Healthcare, UK). Endotoxin levels were reduced (<5 EU/ml) using Vivapure Q maxi H ion exchange columns (Sartorius Stedim, Germany) and confirmed with an Endosafe PTS reader (Charles River Laboratory, USA) as previously described (Middelberg et al., 2011). VP1 capsomeres were assembled into VLPs by dialysis against an assembly buffer then against PBS (Chuan et al., 2008a; Liew et al., 2010; Middelberg et al., 2011). The resultant VLPs were analyzed by asymmetric flow field-flow fractionation coupled to multi angle light scattering (AF4-MALS) using an Eclipse 2 AFFFF system coupled with a Dawn EOS MALS system (Wyatt Technology Corporation, Santa Barbara, USA), and transmission electron microscopy (TEM) using a JEOL 1010 (JEOL Ltd., Tokyo, Japan) to assess size distribution as previously described (Chuan et al., 2008b; Lipin et al., 2008).

**Immunization of Mice**

All animal experiments were approved by the QIMR Berghofer Animal Ethics Committee and were conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (2004). BALB/c mice (n = 10/group) aged 7–8 weeks (Animal Resources Center, WA, Australia) were immunized with the chimeric VLP constructs three times at 3-week intervals by subcutaneous injection at the base of the tail. VLPs were administered at two doses, 10 or 30 µg in independent experiments, and individually or pooled. VLPs were administered without adjuvant as this platform is considered self-adjuvanting (Chackerian et al., 2002; Stanley, 2006). Synthetic peptides corresponding to the epitopes presented by the chimera VP co-administered with 50 µg of high molecular weight poly (I:C) adjuvant (Inivogen, USA) were included as comparator groups in each experiment. In heterologous prime-boost regimens, mice received two doses of 100 µg of PyCSP plasmid DNA (pVR2516, Vical Inc, CA, USA) at 3-week intervals by intramuscular injection into the tibialis anterior muscle, followed by a booster dose of pooled VLP or synthetic peptide in poly(I:C) adjuvant as previously described. In the second experiment, one group received three homologous immunizations with PyCSP plasmid DNA at 100 µg per dose. Control groups included wild-type VLPs, ovalbumin CD8+CD4−, ovalbumin CD8+CD4−, ovalbumin CD8+CD4−, ovalbumin CD8+CD4−, and PBS only (naïve). Immune mice were split into two groups (n = 5/group) to evaluate either immunogenicity using splenocytes for T cell assays or protective efficacy by sporozoite challenge (Figure 1).

**Sporozoite Challenge and Protection**

Two weeks after the final immunization, mice were challenged with 1,000 cryopreserved *P. yoelii* 17 XNL sporozoites (Sanaria Inc, MD, USA) in 200 µl PBS with 2% naive mouse serum administered intravenously into the tail vein. Livers were harvested 42 h post-challenge to assess liver-stage parasite burden as previously described (Schussek et al., 2013). Briefly, livers were homogenized in 5 ml of RLT buffer (Qiagen, Netherlands) supplemented with 1% β-2-mercaptoethanol (Sigma-Aldrich), then RNA was extracted using an RNasey Mini kit (Qiagen) following the manufacturer’s protocol. Using 2.5 µg of RNA, cDNA was synthesized using a Super Script VILO reverse-transcriptase cDNA synthesis kit (Life Technologies, USA) according to manufacturer’s guidelines. Then the *P. yoelii* 18S rRNA and murine housekeeping gene glycerolaldehyde 3-phosphate dehydrogenase (GAPDH) cDNA were quantified using quantitative reverse transcriptase-PCR (qRT-PCR) using a Rotor-gene 3000 (Corbett Research, Mortlake, Australia) with acquisition on the FAM channel. For Py18S cDNA quantification, a Taqman Fast Advanced master mix (Applied Biosystems, Australia) with a custom made Taqman probe (250 nm) (6FAM-CTGGCCCTTTGAGAGCCCACTGATT-BHQ-1) and primers [1 µm] (5’- CTTGGCTCCGGCCTCGATAT and 3’.- TCAAAAGTTACGGAGCCCAATG) (Applied Biosystems). A GAPDH kit (Applied Biosystems) combined with platinum Taq polymerase, PCR buffers (Invitrogen) was used for GAPDH quantification. The data are presented as a ratio of copies of Py18S rRNA per 10^5 copies of GAPDH.

**Splenocyte Harvesting and Stimulation for T Cell Assays**

Ten days after the final immunization, spleens were removed and single cell suspensions were generated by mechanical disruption followed by red blood cell lysis. Splenocytes were then co-incubated with gamma irradiated (16,666 cGy) mouse B cell lymphoma A20 cells (ATCC TIB-208) which were transfected, peptide stimulated, or untreated. Transfections with PyCSP encoded plasmid DNA pVR2516 (Vical, USA) or empty vector pVR1020 (Vical, USA) plasmid DNA was achieved the AMAXA Nucleofector system (Lonzza, Switzerland) using Kit V and program C-25 with 5 x 10^6 A20 cells per cuvette, following the manufacturer’s protocol. Peptide stimulation used either PyCSP CD8+ (280–288) or CD4+ (59–79) T cell epitope synthesized peptides, or these peptides combined with the B cell repeat epitope (QGPGAPQGPGAP) peptide at 10 µg/ml. For this assay, cells were incubated in KD-MEM media comprised of Dulbecco’s Modified Eagle’s Medium (SAFC Global, USA) supplemented with folic acid (136 nM), L-asparagine (32 mM), L-arginine (67 mM), sodium bicarbonate (24 mM), HEPES (10 mM), β-2-mercaptoethanol (5 mM), L-glutamine (1.5 mM), penicillin (100 Units/L), streptomycin (100 mg/L) and 10% fetal calf serum. Each well-contained 5 x 10^5 splenocytes and 1.5 x 10^5 A20 cells in 200 µl of media. Background responses were removed by subtracting transfected pVR1020 wells from pVR2516 wells, and untreated A20 wells from peptide-pulse wells for ELISPOT, cytometric bead array (CBA) and intracellular cytokine staining (ICS) assays.
IFN-γ ELISpot Assay
IFN-γ ELISpot assays were conducted as previously described (Schussek et al., 2017). Briefly, MSIPS4510 multiscreen ELISpot plate (Merck Millipore, Germany) wells were pre-coated with 100 µg/ml anti-mouse IFN-γ (BD Biosciences, USA) then blocked with KD-MEM supplemented with 10% FCS. Quadruplicate wells were used for each stimulation. Plates were incubated for 40 h at 37°C and 5% CO₂. After plate washing, IFN-γ secreting cells were stained with 2 µg/ml biotinylated anti-mouse IFN-γ (BD Biosciences, USA) followed by 1 µg/ml streptavidin-HRP (BD Biosciences, USA). The assay was developed using AEC substrate (BD Biosciences, USA), and spots counted using the AID ELISpot reader system (Autoimmun Diagnostika GmbH, Germany).

Cytometric Bead Array
Splenocyte/A20 cultures were incubated at 37°C and 5% CO₂ for 72 h. Culture supernatant was collected and secreted IFN-γ, TNF, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, and IL-13 cytokines assayed using the mouse cytometric bead array flex kit (BD Biosciences, USA) following the manufacturer’s protocol. Samples were analyzed using a FACSArray instrument (BD Biosciences, USA) using the CBA array software (BD Biosciences, USA).

Intracellular Cytokine Staining
To detect monofunctional or polyfunctional T cell responses, splenocyte/A20 cultures were incubated with 0.1% Golgi Plug (BD Biosciences, USA) for 6 h at 37°C and 5% CO₂. Cells were stained with anti-CD8⁺ (53-6.7) and anti-CD4⁺ (RM4.5) antibodies before being fixed with 1% paraformaldehyde. Cells were then stained with anti-IFN-γ (XMG1.2), anti-IL-2 (JES6-5H4), and anti-TNF-α (MP6-XT22) diluted in permwash buffer (BD Biosciences, USA). All antibodies were purchased from Biologend. Flow cytometric analysis was performed on a Fortessa 4 (BD Biosciences, USA). Post-acquisition data analysis was performed using FlowJo software version 10 (Treestar, USA).

ELISA
Antigen-specific antibody responses were detected by ELISA using the PycSP B cell repeat peptide linked to a polystyrene binding tag (Kumada et al., 2010) with a glycine spacer (Kogot et al., 2012) (PST-B cell, RIIIRRGGG-GQPGAPx3) (Mimotopes, Australia). The PST-tag with a glycine spacer was incorporated to enhance attachment of the peptide to the plate and expose the B cell repeat for antibody recognition. Nunc maxisorp plates (Thermo Fisher Scientific, USA) were coated overnight with the PST-B cell peptide (5 µg/ml) in a carbonate coating buffer, then blocked with PBS containing 2% BSA. Triplicate wells of sera from mice were titrated by 2-fold dilutions in PBS-BSA 0.1%, and then incubated with biotinylated donkey α-mouse IgG (Jackson ImmunoResearch Laboratories, USA) diluted in PBS-BSA 0.1%, followed by an incubation with streptavidin-HRP (BD Biosciences, USA) diluted 1:1,000 in PBS-BSA 0.1 and 0.2% Tween20. Plates were developed with tetramethylbenzidine (TMB) and stopped using TMB stop reagent (Sigma Aldrich, USA). Absorbance was measured at 450 nm using a VersaMax microplate reader (Molecular Devices, USA). Positive results were recorded if OD₄₅₀ values were > 3 standard deviations above the mean blank (no serum) values.
**Statistical Analysis**

Statistical analysis was performed using GraphPad Prism version 6.0 (GraphPad, CA, USA). Logarithmic transformed data of groups were compared by one-way analysis of variance (ANOVA) and Bonferroni's multiple comparison test. Statistical significance is displayed as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

**RESULTS**

**VLP Construction**

In-frame genomic insertion of antigen-derived epitopes into the MuPyV-VP1 protein was confirmed by sequencing. After the VLPs were assembled in vitro, analysis using AF4-MALS showed only small amounts of protein aggregation and TEM images confirmed that the chimeras had a similar morphology to wild-type VLPs (Figure 2). The mean radius of each of the chimeric VLPs was similar to that of the wild type VLPs [Wild type- 21.00 ± 1.27 nm; CD8 VLPs- 20.51 ± 0.67 nm; CD4 VLPs- 21.07 ± 0.61 nm; B cell VLPs- 20.85 ± 0.67 nm (mean radius ± SD)].

**VLP-Induced T Cell Immune Responses**

Mice were immunized with chimeric CD8 or CD4 VLPs to assess their capacity independently to induce CD8+ or CD4+ T cell responses, and to evaluate if pooling of the VLPs would result in an additive or synergistic response. Pooled VLPs were evaluated in independent experiments at 10 µg per dose and at 30 µg per dose to dose-match the independent VLPs (Figure 1).

IFN-γ responses detected by ELISpot showed that homologous immunization with the CD8 VLP induced significant IFN-γ spot forming cells (SFCs) when stimulated with pooled peptide or PyCSP transfected A20 cells (p < 0.001) (Figures 3A, 4A). The magnitude of VLP-induced CD8+ T cell response was similar to that induced by CD8 peptide immunization when stimulated by peptide (but not transfected A20 cells). In contrast, the CD4 VLP failed to induce a significant IFN-γ response (Figures 3A, 4A); robust responses against peptide (p < 0.0001) and transfected stimulation (p < 0.001) were observed in mice immunized in parallel with CD4 peptides in adjuvant (Figure 3A) and similarly in the subsequent experiment (Figure 4A).

Immunization with pooled CD8 plus CD4 VLPs resulted in a similar IFN-γ profile to that induced by the individual VLPs, with a robust response to the CD8 peptide and negligible response to the CD4 peptide (Figure 4A).

Heterologous prime-boost immunization with DNA prime/VLP boost induced a stronger response than homologous VLP immunization (Figures 3A–C). This was attributed to the plasmid DNA prime with the homologous DNA regimen inducing the most robust response (Figures 4A–C). The reduction in responses between the DNA only and DNA prime/VLP boost could be due to an inhibition caused by VLPs, but more likely that the third dose of DNA was more immunogenic than the VLPs.

The profile of IFN-γ responses detected with both CBA and ICS readouts was similar to that shown by ELISpot for the CD8 and CD4 VLPs (Figures 3A–C, 4A–C). Robust IFN-γ responses induced by the CD8 VLP were similar to that induced by peptide in adjuvant. Negligible CD4+ T cell responses were induced by CD4 VLP immunizations, as opposed to the robust CD4+...
T cell responses which were evident following CD4 peptide immunization. This differentiation is likely due to the reduced actual peptide load in the CD4 VLPs of approximately 0.52 μg.  

TNF was induced in mice immunized with the CD4 peptide individually or in pools (Figures 3C, 4C). TNF was also significantly induced by DNA immunizations in response to pooled peptide (p < 0.01) and CD4 peptide stimulation (p < 0.0001). No VLP immunizations resulted in significant TNF or IL-2 production from stimulated splenocytes. Our CBA assessed a range of cytokines specifically: IFN-γ, IL-10, IL-12p70, IL-13 and TNF. However, with the exception of IFN-γ and TNF, we only detected a very low level of cytokines induced by our VLP immunizations (data not shown).  

**VLP-Induced Antibody Responses**  
The B cell VLP was predicted to induce strong antibody responses since it comprised the dominant PyCSP B cell linear epitope exposed on the surface of the VLP in a repetitive array. Responses to the B cell VLP were assessed in parallel individually as well as in a pool with the CD8 and CD4 VLPs since it was anticipated that the inclusion of the CD4 VLP would enhance the epitope-specific antibody titer.  

Robust anti-PyCSP B cell peptide IgG responses were induced by all groups containing the B cell VLP (p < 0.0001 relative to naive) (Figure 5). In the homologous VLP immunizations, there were no significant differences between any groups indicating no additive effect by including the CD4 VLP. VLP-induced antibody responses were significantly higher than homologous DNA immunizations (p < 0.0001). In the DNA prime/VLP boost regimen, the response induced by the 10 μg/construct boost was significantly higher as compared to the 30 μg/construct boost (p < 0.01); conversely in the homologous VLP only groups, the 30 μg per dose group higher than the 10 μg per dose, although not significantly different.  

**Protection From Sporozoite Challenge**  
To evaluate the protective efficacy of chimeric VLPs, VLP-immunized mice (n = 5/group) were challenged with 1,000 P. yoelii 17XNL sporozoites. In the first experiment, 40% (2/5) mice immunized with DNA prime / VLP boost had no parasite RNA detected in their liver and there was a 38% reduction in liver-stage parasite burden relative to the PBS control group overall in the group; these differences were not significant given the relatively small group sizes. When the experiment was repeated using the higher dose pooled VLPs (30 μg/construct), a significant reduction in parasite burden was noted in mice immunized with the heterologous DNA prime / VLP pooled VLP regimen (p < 0.01) (Figure 6). This equates to a mean 72% reduction in the liver parasite burden relative to the PBS immunized group. In the pooled VLP immunized mice, there was a mean 57% reduction in liver-stage parasite burden relative to the PBS control, although this did not reach statistical significance.  

**DISCUSSION**  
Development of an efficacious malaria vaccine has been challenging, with even the most advanced candidate Mosquirix™ showing very poor efficacy despite very
FIGURE 4 | Cellular immune responses induced by individual (30 µg) or pooled (30 µg each) chimeric VLP immunizations. BALB/c mice (n = 5/group) received three immunizations at 3 week intervals with three homologous i.m., PyCSP plasmid DNA (100 µg) immunizations or a prime/boost regimen using two i.m., priming immunizations with PyCSP plasmid DNA (100 µg) followed by a single s.c. boost using either pooled PyCSP VLPs (30 µg each) or pooled PyCSP peptides (30 µg each) with poly(I:C); wild type VLPs (30 µg); pooled ovalbumin peptides (30 µg each) with poly(I:C); or PBS only. (A) IFN-γ ELISPOT, (B) ICS, and (C) CBA responses were assayed as described in the legend to Figure 3, using individual CD8 peptides or CD4 peptides, pooled peptides, or DNA-transfected A20 cells. All data sets are presented as group means + SEM (media only subtracted). Statistical comparisons are made to the PBS control group, and between homologous VLP and peptide immunization groups using log-transformed data with significance determined using one-way ANOVA followed by Bonferroni’s post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (nt, not tested).

extensive refinement during preclinical development and early stage clinical testing (Tinto et al., 2015; Olotu et al., 2016). Mosquirix™ is a chimeric VLP construct expressing the central repeat region plus the entire C-terminal flanking region (amino acids 207–395) of the P. falciparum CSP fused to the hepatitis B virus surface antigen, HBsAg. Protection has been associated with antibodies or CD4+ T cell responses, but this vaccine fails to induce CD8+ T cell responses which are thought to be required for protection against intracellular pathogens such as the Plasmodium spp. parasite (Seder and Hill, 2000). Various Plasmodium targets have been evaluated using a range of subunit vaccine delivery platforms including recombinant protein, recombinant viruses, synthetic peptides, plasmid DNA, nanoparticles, and VLPs [reviewed in Draper et al. (2015)]. However, none of these platforms have induced robust CD8+ and CD4+ T cell responses as well as antibody responses sufficient for protection against malaria. In other disease models, VLP vaccines show potential for induction of broad antibody and cellular immune responses.

Protection directed against the pre-erythrocytic stage of the Plasmodium lifecycle following sporozoite challenge can be achieved primarily by antibody responses which inhibit sporozoite infection of the hepatocyte (Majarian et al., 1984; Charoenvit et al., 1991) or CD8+ T cell responses which act directly or indirectly upon the liver-stage parasite (Weiss et al., 1988, 1990, 1992; Doolan and Hoffman, 2000); moreover, there is evidence that induction of CD4+ T cell responses is required for optimal efficacy (Weiss et al., 1993). There is increasing interest in immunization regimens which induce liver-resident memory T cells as the parasite-infected liver is considered the primary site
It is possible that immune responses measured in the periphery or in splenocytes may not accurately reflect the vaccine-induced responses in the liver, so future studies should consider evaluation of liver-resident memory T cells in addition to the more traditional readouts from splenocytes.

Many VLP vaccine platforms have been developed, using structural proteins from various viral species. VLPs based on the murine polyomavirus are considered a promising VLP for vaccine development because of their reported humoral immunogenicity and their ability to be produced reproducibly with high yields (Chuan et al., 2008a; Liew et al., 2010, 2012; Middelberg et al., 2011; Anggraeni et al., 2013; Rivera-Hernandez et al., 2013; Wibowo et al., 2014; Seth et al., 2016; Tekewe et al., 2017). However, their capacity to induce robust antibody plus CD4⁺ and CD8⁺ T cell responses has not been thoroughly investigated. Accordingly, we evaluated both cellular and antibody responses using chimeric murine polyomavirus VLPs incorporating the CSP as a vaccine delivery platform, in the P. yoelii murine model.

It is well-established that VLPs are very effective at inducing antigen-specific antibody responses [reviewed in Grgacic and Anderson (2006)] likely due to their ability cross-link B cell surface receptors (Thônes et al., 2008) acting in a T cell independent manner (Snapper and Mond, 1993; Szomolanyi-Tsuda and Welsh, 1998). Consistent with that, herein we showed that our B cell VLP induced high IgG titres against the Pyc CSP B cell epitope. There was a significant decrease in antibody titers in the DNA prime/VLP boost group when the pooled VLP component was increased from 10 to 30 μg per VLP. In both experiments, mice were challenged 2 weeks after the final immunization by i.v., injection of 1,000 P. yoelii 17XNL cryopreserved sporozoites. Parasite burden was assessed by qRT-PCR analysis of Py18s rRNA extracted from livers harvested 42 h post-challenge and calculated as a ratio to the GAPDH housekeeping-gene mRNA. Results for individual mice are shown, with bars representing the group mean. The dotted line represents the naïve mouse mean. Log-transformed ratio data was analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test. **p < 0.01.
were able to induce moderate levels of IFN-γ directed against the CD8+ T cell epitope presented as a synthetic peptide or in the context of whole antigen transfected, with both ELISpot and ICS (Figures 3A,C, 4A,C). This antigen-specific recognition confirms that the CD8 chimeric VLP presented the incorporated CD8+ T cell epitope in vivo to naive CD8+ T cells, and that this presentation was via MHC class I molecules (Heath et al., 2004). These results are consistent with previous studies reporting that chimeric VLPs incorporating a single CD8+ T cell epitope from viral or ovalbumin targets induced CTL activity mediated by CD8+ T cells (Sedlik et al., 1997; Crisci et al., 2009).

It is possible that our immunizations with pooled VLPs using 30 μg of each construct failed to protect mice from challenge as the induced CD8+ T cell response was insufficient to protect (Schmidt et al., 2008) with a mean frequency of 0.59% of CD8+ T cells expressing IFN-γ (Figure 4B).

We had anticipated that immunizing with a pool of VLPs which included the CD4 T cell peptide might result in an additive or synergistic response, as noted for immunization with a pool of the synthetic peptides. However, there was no evidence of any additive or synergistic effects on CD8+ T cell responses when VLPs were administered as a pool with the CD4 VLP; this was likely due to the very low responses induced by the CD4 VLP. The carrier MuPyV VP1 protein is likely to contain CD8+ T helper epitopes similar to those in the HBV core protein (Schödel et al., 1992; Bickert et al., 2007) and may provide carrier-related T cell help for antibody responses, but those would provide no antigen-specific help against challenge by the Plasmodium parasite. Poly(I:C) was selected to adjuvant the synthetic peptides in vivo because it is a known inducer of type I (Salem et al., 2005; Qiu and Cui, 2007; Coffman et al., 2010; Schneider-Obrun et al., 2011) and II (Tewari et al., 2010; Kastenmüller et al., 2013) cellular responses. However, VLPs are generally considered self-adjuvating due to their viral structure (Stanley et al., 2006; Chackerian, 2007). There are however contradictory reports, with some reports showing that adjuvants are essential (Storni et al., 2002), beneficial (Freysschmidt et al., 2004; Ding et al., 2009) or not necessary (Mazeik et al., 2012; Rivera-Hernandez et al., 2013; Kawan et al., 2014). In our studies, we elected to exclude adjuvants so as to better understand the immunogenicity of our chimeric VLPs. We cannot however rule out the possibility that administration of the CD4 VLP with poly(I:C) could have enhanced the VLP-induced T cell response, but other data generated in our laboratory showed no enhancement of CD4+ T cell when pooled VLPs were co-administered with poly(I:C) (manuscript in preparation).

In our VLP constructs, each T cell epitope was inserted into surface-exposed regions of the VP1 protein, since we predicted that epitopes inserted into this region would be less likely to interfere with VLP formation. It is possible that this location may not have been optimal for the induction of cellular immune responses and that placing the epitopes on terminal regions may have been beneficial, as reported in one study in a chimeric calicivirus-like VLP system with ovalbumin CD8 epitopes showing significantly higher IFN-γ responses, target-specific lysis and protection (Crisci et al., 2009). It is also possible that the lack of responses to the CD4 epitope may have been a dose related issue; the CD4 peptide component of the 30 μg VLP dose was approximately 0.52 μg peptide epitope equivalent, whereas the peptide immunized mice received nearly 60 times the epitope per dose. Our immunogenicity assessments used lymphocytes taken from spleen and not draining lymph nodes, but the strong responses detected in splenocytes from the peptide-immunized mice would be expected to accurately reflect a response in the draining lymph nodes; if the VLPs induced a robust CD4+ T cell response then this should also have been detected in splenocytes.

To evaluate the protective capacity of our chimeric VLPs, we harvested livers 42h post-sporozoite challenge, at the late liver-stage of the P. yoelii lifecycle before parasites were expected to release into the blood (Baer et al., 2007). This timeframe maximized the opportunity for VLP-induced protective immune responses to clear parasite-infected cells. Liver-stage protection has previously been achieved by adoptively transferring a CD8+ T cell clone (Weiss et al., 1988), or by passive transfer of monoclonal antibodies specific to the PyCSP central repeat (Charoenvit et al., 1991). These protective antigenic epitopes were incorporated within our VLP chimeras, and generated epitope-specific CD8+ T cell and antibody responses. In our study, there was evidence that VLPs could induce protection against sporozoite challenge since sterile protection was seen in 2 of 5 mice and there was a reduction in parasite load; however, this protection was suboptimal. Our immunological data supports the induction of the type of immune response required to protect against Plasmodium sporozoite challenge, but the magnitude of those VLP-induced responses may have been insufficient to reach a protective threshold (Schmidt et al., 2010).

This is consistent with other studies where protection correlated with the number of adoptively transferred clonal CD8+ T cells where 20 × 10^6 cells were required for sterile protection (Weiss et al., 1992), or with the number of memory CD8+ T cells stimulated by immunizations (Schmidt et al., 2008, 2010), or with the amount of passive transferred monoclonal antibodies (Charoenvit et al., 1991).

Indeed, we found that more robust antibody and cellular responses were induced by a prime/boost regimen as compared with homologous VLPs, and we anticipate that this would be further enhanced with the inclusion of a second VLP boost.

Overall, our data showed that the MuPyV chimeric VLP platform is capable of inducing antigen-specific antibody responses, and established for the first time for this vaccine platform, their capacity to induce CD8+ T cell immune responses. Future studies could evaluate alternative epitope insertion sites within the MuPyV VP1 protein to determine if other sites enhance cellular immune responses, or the inclusion of adjuvants in the vaccination regimen. Additional regions of the target antigens (e.g., repetitive regions targeted by antibody responses, together with T helper epitopes) could also be included. Alternative target antigens could be also evaluated since studies have suggested that multiple antigen targets may be required for protection from Plasmodium challenge (Doolan et al., 1996; John et al., 2005; Osier et al., 2008). With approximately 2,000 active genes, and 816 identified proteins present during Plasmodium liver-stage of infection (Tarun et al.,
part of the challenge is to identify the most optimal target antigens for induction of vaccine-induced protective immunity (Schussek et al., 2017).

DATA AVAILABILITY
The datasets generated for this study can be obtained from the corresponding author upon reasonable request.

ETHICS STATEMENT
All animal experiments were approved by the QIMR Berghofer Animal Ethics Committee and were conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (2004).

AUTHOR CONTRIBUTIONS
DP, SA, DD, and AM contributed conception and design of the study. DP, NW, YC, TR-H, LL, and AM contributed to construction of virus-like particles. DP, SA, and PG conducted mouse experiments. DP performed the statistical analysis. DP wrote the first draft of the manuscript. DD and SA edited the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING
This research was funded by the National Health and Medical Research Council (NHMRC) Program grant #1037304, and by an Australian Infectious Diseases UQ-QIMR Seed funding grant. DD was supported by a NHMRC Principal Research Fellowship #1023636. DP was supported by an Australian Postgraduate Award.

ACKNOWLEDGMENTS
The authors thank Professor Robert Garcea (University of Colorado, CO, USA) for the plasmid containing the MuPyV-VP1 protein, and Dr. Stephen Hoffman and colleagues (Sanaria Inc., Rockville, MD, USA) for providing cryopreserved sporozoites. TEM images were taken by Alice Lei Yu from the University of Queensland, Australia.
Gola, A., Silman, D., Walters, A. A., Sridhar, S., Uederhart, S., and Salman, A. M., et al. (2018). Prime and target immunization protects against liver-stage malaria in mice. *Sci. Transl. Med.* 10, 460. doi: 10.1126/scitranslmed.aap9128

Gordon, D. M., McGovern, T. W., Krzych, U., Cohen, J. C., Schneider, I., LaChance, R., et al. (1995). Safety, immunogenicity, and efficacy of a recombinant virus-like particle (VLP) of Plasmodium falciparum circumsporozoite-protein hepatitis-b-surface-antigen subunit vaccine. *J. Infect. Dis.* 171, 1576–1585. doi: 10.1093/infdis/171.6.1576

Gracy, E. C., and Anderson, D. A. (2006). Virus-like particles: passport to immune recognition. *Methods* 40, 60–65. doi: 10.1016/j.ymeth.2006.07.018

Grillot, D., Michel, M., Müller, I., Tougue, C., Rénia, L., Mazier, D., et al. (1990). Immune responses to defined epitopes of the circumsporozoite protein of the murine malaria parasite, *Plasmodium yoelii*. *Eur. J. Immunol.* 20, 1215–1222. doi: 10.1002/eji.1830200604

Heath, W. R., Bela, G. T., Behrens, G. M., Smith, C. M., Forehand, S. P., Parish, I. A., et al. (2004). Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. *Immunol. Rev.* 199, 9–26. doi: 10.1111/j.0105-2896.2004.01042.x

Janitzek, C. M., Matondo, S., Thrane, S., Nielsen, M. A., Kavishe, R., Mwakalinga, G., Grgacic, E. V., and Anderson, D. A. (2006). Virus-like particles: passport to immune recognition. *Methods* 40, 60–65. doi: 10.1016/j.ymeth.2006.07.018

Kushnir, N., Streatfield, S. J., and Yusibov, V. (2012). Virus-like particles as immune recognition. *J. Immunol. Methods*. 377, 47–52. doi: 10.1016/j.jim.2012.01.009

Noe, A. R., Espinosa, D., Li, X., Coelho-Dos-Reis, J. G., Funakoshi, R., Giardina, S., et al. (2014). A full-length *Plasmodium falciparum* recombinant circumsporozoite protein expressed by *Pseudomonas fluorescens* platform as a malaria vaccine candidate. *PLoS ONE* 9(10):e107764. doi: 10.1371/journal.pone.0107764

Ochsliäger, P., Olsen, W., Dell, K., Faath, S., Garcia, R. L., Jochmus, I., et al. (2003). Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in *C57BL/6* mice. *J. Virol.* 77, 4635–4645. doi: 10.1128/JVI.77.8.4635-4645.2003

Okot, O., Fegan, G., Wambua, J., Nyangweso, G., Leach, A., Lievens, M., et al. (2016). Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children. *N Engl. J. Med.* 374, 2519–2529. doi: 10.1056/NEJMoa1512577

Olsen, T. M., Stone, B. C., Chuenchob, V., and Murphy, S. C. (2018). Prime-and-trap malaria vaccine to generate protective CD8(+) liver-resident memory T cells. *J. Immunol.* 201, 1984–1993. doi: 10.4049/jimmunol.1800740

Osier, F. H., Fegan, G., Polley, S. D., Murungi, L., Verra, F., Tetteh, K. K., et al. (2008). Breadth and magnitude of antibody responses to multiple *Plasmodium falciparum* merozoite antigens are associated with protection from clinical malaria. *Infect. Immun.* 76, 2240–2248. doi: 10.1128/IAI.01185-07

Qui, F., and Cui, Z. (2007). CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(C)C-adjuvanted MHC I-restricted peptide epitope. *J. Immunother.* 30, 180–189. doi: 10.1097/01.jim.0000211330.61019.6f

Rivera-Hernandez, T., Hartas, J., Wu, Y., Chuan, Y. P., Lua, L. H., Good, M., et al. (2013). Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). *Vaccine* 31, 1950–1955. doi: 10.1016/j.vaccine.2013.02.013

Salem, M. L., Kadima, A. N., Cole, D. J., and Gillanders, W. E. (2005). Defining the antigen-specific T-Cell response to vaccination and poly (C)C/TLR3 signaling - evidence of enhanced primary and memory CD8 T-Cell responses and antimurine immunity. *J. Immunother.* 28, 220–228. doi: 10.1097/01.jim.0000156288.75196.0d

Salunke, D. M., Caspar, D. L., and Garcea, R. L. (1986). Self-assembly of purified polyomavirus capsid protein VP1. *Cell* 46, 895–904. doi: 10.1016/0092-8674(86)90071-1

Schmidt, N. W., Butler, N. S., Badovinac, V. P., and Harty, J. T. (2010). Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. *PLoS Pathog.* 6(e1000998). doi: 10.1371/journal.ppat.1000998

Schmidt, N. W., Podymoingin, R. L., Butler, N. S., Badovinac, V. P., Tucker, B. J., Bahjat, K. S., et al. (2008). Memory CD8 T-cell responses exceeding a large but definable threshold provide long-term immunity to malaria. *Proc. Natl. Acad. Sci. U.S.A.* 105, 14017–14022. doi: 10.1073/pnas.080545 52105

Schneider-Ohrum, K., Giles, B. M., Weirbach, H. K., Williams, B. L., DeAlmeida, D. R., and Ross, T. M. (2011). Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines. *Vaccine* 29, 7154–7162. doi: 10.1016/j.vaccine.2011.02.013

Schödel, F., Moriarty, A. M., Peterson, D. L., Zheng, J. A., Hughes, J. A., Will, H., et al. (1992). The position of heterologous epitopes inserted in hepatitis-B virus core particles determines their immunogenicity. *Infect. Immun.* 60, 2–10.

Schusske, S., Groves, P. L., Apte, S. H., and Doolan, D. L. (2013). Highly sensitive quantitative real-time PCR for the detection of Plasmodium liver-stage parasite burden following low-dose sporozoite challenge. *PLoS ONE* 8:e77811. doi: 10.1371/journal.pone.0077811

Schusske, S., Trieu, A., Apte, S. H., Sidney, J., Sette, A., and Doolan, D. L. (2017). Novel *Plasmodium antigens* identified via genome-based antibody
screen induce protection associated with polyfunctional T cell responses. Sci. Rep. 7:18. doi: 10.1038/s41598-017-13554-0

Sedegah, M., Hedstrom, R., Hobart, P., and Hoffman, S. L. (1994). Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl. Acad. Sci. U.S.A. 91, 9866–9870. doi: 10.1073/pnas.91.21.9866

Seder, R. A., and Hill, A. V. (2000). Vaccines against intracellular infections requiring cellular immunity. Nature 406, 793–798. doi: 10.1038/35021239

Sedlik, C., Baran, M., Sarraseca, J., Casal, I., and Leclerc, C. (1997). Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicating exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. U.S.A. 94, 7503–7508. doi: 10.1073/pnas.94.14.7503

Seth, A., Kong, I. G., Lee, S. H., Yang, J. Y., Lee, Y. S., Kim, Y., et al. (2016). Modular virus-like particles for sublingual vaccination against group A streptococcus. Vaccine 34, 6472–6480. doi: 10.1016/j.vaccine.2016.11.008

Snapper, C. M., and Mond, J. J. (1993). Towards a comprehensive view of immunoglobulin class switching. Immunol. Today 14, 15–17. doi: 10.1016/0167-5699(93)90318-F

Stanley, M., Lowy, D. R., and Frazer, I. (2006). Human papillomavirus vaccines: underlying mechanisms. Vaccine 24(Suppl 3), 106–113. doi: 10.1016/j.vaccine.2006.05.110

Stanley, M. A. (2006). Human papillomavirus vaccine. Rev. Med. Virol 16, 139–149. doi: 10.1002/rmv.498

Storm, T., Lechner, F., Erdmann, A., Bächi, T., Jegerlehner, A., Dumrese, T., et al. (2002). Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J. Immunol. 168, 2880–2886. doi: 10.4049/jimmunol.168.6.2880

Szomolanyi-Tuda, E., and Welsh, R. M. (1998). T-cell-independent antiviral antibody responses. Curr. Opin. Immunol. 10, 431–435. doi: 10.1016/S0952-7915(98)80117-9

Tamminga, C., Sedegah, M., Regis, D., Chuang, L., Epstein, J. E., Spring, M., et al. (2011). Adenovirus-5 vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS ONE 6 e25868. doi: 10.1371/journal.pone.0025868

Tarun, A. S., Peng, X., Dumpit, R. F., Ogata, Y., Silva-Rivera, H., Camargo, N., et al. (2008). A combined transcriptome and proteome study of malaria parasite liver stages. Proc. Natl. Acad. Sci. U.S.A. 105, 305–310. doi: 10.1073/pnas.0707810104

Tegerstedt, K., Lindencrona, J. A., Curcio, C., Andreasson, K., Tullus, C., Forini, G., et al. (2005). A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res. 65, 3953–3957. doi: 10.1158/0008-5472.CAN-05-0335

Tekewe, A., Fan, Y., Tan, E., Middelberg, A. P., and Lua, L. H. (2017). Integrated molecular and bioprocess engineering for bacterially produced immunogenic modular virus-like particle vaccine displaying 18 kDa rotavirus antigen. Biotechnol. Bioeng. 114, 397–406. doi: 10.1002/bit.26068

Tewari, K., Flynn, B. J., Boscardin, S. B., Kastenmueller, K., Salazar, A. M., Anderson, C. A., et al. (2010). Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CS in non human primates. Vaccine 28, 7256–7266. doi: 10.1016/j.vaccine.2010.08.098

Thönnes, N., Herreiner, A., Schädlich, L., Piuko, K., and Müller, M. (2008). A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomers than viruslike particles with respect to the induced antibody response. J. Virol. 82, 5472–5485. doi: 10.1128/JVI.02482-07

Tinto, H., D’Alessandro, U., Sorgho, H., Valea, I., Tahita, M. C., Kabore, W., et al. (2015). Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45. doi: 10.1016/S0140-6736(15)60721-8

Weish, D. S., Gettryacamit, M., Leitner, W. W., Lyon, J. A., Stewart, V. A., Marit, G., et al. (2006). Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A. Vaccine 24, 4167–4178. doi: 10.1016/j.vaccine.2006.02.041

Weiss, W. R., Berzofsky, J. A., Houghten, R. A., Sedegah, M., Hollindale, M., and Hoffman, S. L. (1992). A T-cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J. Immunol. 149, 2103–2109.

Weiss, W. R., Mellouk, S., Houghten, R. A., Sedegah, M., Kumar, S., Good, M. F., et al. (1990). Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J. Exp. Med. 171, 763–773. doi: 10.1084/jem.171.3.763

Weiss, W. R., Sedegah, M., Beaudoin, R. L., Miller, L. H., and Good, M. F. (1988). CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. U.S.A. 85, 573–576. doi: 10.1073/pnas.85.2.573

Weiss, W. R., Sedegah, M., Berzofsky, J. A., and Hoffman, S. L. (1993). The role of CD4+ T cells in immunity to malaria sporozoites. J. Immunol. 151, 2690–2698.

Wibowo, N., Hughes, F. K., Fairmaid, E. J., Lua, L. H., Brown, L. E., and Middelberg, A. P. (2014). Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes. Vaccine 32, 3651–3655. doi: 10.1016/j.vaccine.2014.04.062

World Malaria Report (2017). World Health Organization. Available online at: http://www.who.int/malaria/publications/world-malaria-report-2017/en/ (accessed January 25, 2019).

Yoshida, K., Iyori, M., Blagborough, A. M., Salman, A. M., Dulap, P., Sala, K. A., et al. (2018). Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. Sci. Rep. 8:3896. doi: 10.1038/s41598-018-21369-y

Conflict of Interest Statement: The University of Queensland (UQ) filed patents on the use of MuPyV as a vaccine platform. LL and AM contributed to those patents and, through their employment with UQ, hold an indirect interest in this intellectual property.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Pattinson, Apte, Wibowo, Chuan, Rivera-Hernandez, Groves, Lua, Middelberg and Doolan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.